BR112019003811A2 - composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição - Google Patents
composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composiçãoInfo
- Publication number
- BR112019003811A2 BR112019003811A2 BR112019003811-6A BR112019003811A BR112019003811A2 BR 112019003811 A2 BR112019003811 A2 BR 112019003811A2 BR 112019003811 A BR112019003811 A BR 112019003811A BR 112019003811 A2 BR112019003811 A2 BR 112019003811A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- need
- formula
- composition
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/398—Electrooculography [EOG], e.g. detecting nystagmus; Electroretinography [ERG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662380325P | 2016-08-26 | 2016-08-26 | |
US62/380,325 | 2016-08-26 | ||
US201762477435P | 2017-03-28 | 2017-03-28 | |
US62/477,435 | 2017-03-28 | ||
US201762501696P | 2017-05-04 | 2017-05-04 | |
US62/501,696 | 2017-05-04 | ||
PCT/US2017/048748 WO2018039642A1 (en) | 2016-08-26 | 2017-08-25 | Compositions and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019003811A2 true BR112019003811A2 (pt) | 2019-05-21 |
Family
ID=61245395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019003811-6A BR112019003811A2 (pt) | 2016-08-26 | 2017-08-25 | composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição |
Country Status (11)
Country | Link |
---|---|
US (2) | US11103499B2 (pt) |
EP (1) | EP3503879A4 (pt) |
JP (1) | JP7096813B2 (pt) |
KR (1) | KR102374044B1 (pt) |
CN (1) | CN109890371A (pt) |
AU (1) | AU2017315947B2 (pt) |
BR (1) | BR112019003811A2 (pt) |
CA (1) | CA3034895A1 (pt) |
RU (1) | RU2764716C2 (pt) |
TW (1) | TW201815387A (pt) |
WO (1) | WO2018039642A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478467B2 (en) * | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
RU2760558C9 (ru) * | 2017-05-04 | 2022-02-22 | Эксива Гмбх | Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения |
ES2909388T3 (es) * | 2017-09-07 | 2022-05-06 | Otsuka Pharma Co Ltd | Procedimiento industrial de monoalquilación de un nitrógeno de piperidina en derivados de piperidina con alquilo deuterado |
EP3753557A4 (en) | 2018-02-15 | 2021-12-01 | National University Corporation Chiba University | PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES |
JP2021523228A (ja) | 2018-05-04 | 2021-09-02 | パーセプション ニューロサイエンス,インコーポレイティド | 物質乱用の治療方法 |
JP2022526101A (ja) * | 2019-03-18 | 2022-05-23 | アヴェニール ファーマシューティカルズ, インコーポレイテッド | 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法 |
EP4153564A4 (en) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
CN111548279A (zh) * | 2020-05-27 | 2020-08-18 | 上海凌凯医药科技有限公司 | 一种2-(二甲氨基)-3-(2-(3-甲氧基苯乙基)苯氧基)丙-1-醇的合成方法 |
CN113284553B (zh) * | 2021-05-28 | 2023-01-10 | 南昌大学 | 一种用于治疗药物成瘾的药物靶点结合能力测试方法 |
WO2023028086A1 (en) * | 2021-08-23 | 2023-03-02 | Gilgamesh Pharmaceuticals, Inc. | Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists |
WO2023108172A2 (en) * | 2021-12-11 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 4-substituted-2,5-dimethoxyamphetamine |
CN114560630B (zh) * | 2022-03-10 | 2024-07-05 | 南京拓灵智能科技有限公司 | 一种防污玻璃杯及其制备方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2133894A (en) | 1938-10-18 | Process fob improving drying | ||
US2780355A (en) | 1953-11-09 | 1957-02-05 | Scherer Corp R P | Gelatin capsule containing water soluble substances |
US4221778A (en) | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
US4762709A (en) | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
EP0205336B1 (en) | 1985-06-11 | 1991-09-11 | Teijin Limited | Oral sustained release pharmaceutical preparation |
US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
DE3613975A1 (de) | 1986-04-25 | 1987-10-29 | Bayer Ag | Trennung von diastereomeren |
US4959219A (en) | 1988-08-15 | 1990-09-25 | Fisons Corporation | Coating barriers comprising ethyl cellulose |
US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5186930A (en) | 1988-11-14 | 1993-02-16 | Schering Corporation | Sustained release oral suspensions |
US4999189A (en) | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
US5196436A (en) * | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
DE4406424A1 (de) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
PL189256B1 (pl) | 1996-03-29 | 2005-07-29 | Duphar Int Res | Związki piperazyny i piperydyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te związki, zastosowanie tych związków do wytwarzania leków |
US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
GB9706753D0 (en) | 1997-04-03 | 1997-05-21 | Pharmacia & Upjohn Spa | Aralkoxy-morphinan derivatives |
IN186245B (pt) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
SK286778B6 (sk) | 2000-05-12 | 2009-05-07 | Solvay Pharmaceuticals B. V. | Piperazínové a piperidínové zlúčeniny, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú, a použitie týchto zlúčenín |
EP1341799B1 (en) | 2000-12-13 | 2005-03-16 | Warner-Lambert Company LLC | P-chirale bisphospholane ligands, their transition metal complexes |
CA2473536A1 (en) | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
EP2529758A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
WO2005054194A1 (en) | 2003-11-25 | 2005-06-16 | Texcontor Etablissement | A method for the preparation of (2s, 3ar, 7as)-octahydro-1h-indole-2-carboxylic acid as key intermediate in the preparation of trandolapril by reacting a cyclohexyl aziridine with a dialkyl malonate |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
FR2873294B1 (fr) * | 2004-07-26 | 2008-05-09 | Greenpharma Sa Sa | Association de medicaments |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
US7119211B2 (en) | 2004-09-23 | 2006-10-10 | Yamakawa Chemical Industry Co., Ltd. | Process for preparing optically active 3-(methylamino)-1-(2-thienyl) propan-1-ol and intermediates for preparation |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US7750013B2 (en) | 2005-08-22 | 2010-07-06 | Solvay Pharmaceuticals, B.V. | N-oxides as prodrugs of piperazine and piperidine derivatives |
US8075777B2 (en) | 2007-05-16 | 2011-12-13 | E. I. Du Pont De Nemours And Company | Process for the separation of diastereomers |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US8785472B2 (en) | 2010-05-11 | 2014-07-22 | National Cheng Kung University | Use of dextromethorphan in treating addictive behavior or bipolar disorder |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
CN102813664A (zh) * | 2011-06-12 | 2012-12-12 | 王定豪 | 包含格雷类药物和阿司匹林的口服肠溶制剂 |
CA2897571C (en) | 2013-01-21 | 2018-12-18 | Apparao Satyam | Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group |
CN105491885B (zh) * | 2013-03-07 | 2018-09-25 | 思想实验室有限责任公司 | 疼痛药物组合及其用途 |
CN103242179B (zh) | 2013-05-08 | 2014-12-17 | 深圳万乐药业有限公司 | 一种高纯度盐酸沙格雷酯的制备方法 |
KR101585189B1 (ko) | 2013-07-18 | 2016-01-13 | 주식회사 대희화학 | 사포그릴레이트 염산염 결정형 ⅱ의 제조방법 |
CN105327349A (zh) * | 2014-06-18 | 2016-02-17 | 上海翰森生物医药科技有限公司 | Nmda受体拮抗剂的医药用途及其药物组合物 |
CN104667283B (zh) * | 2015-03-09 | 2018-04-13 | 中国药科大学 | 一种治疗血脂异常和动脉粥样硬化的复方药物组合 |
-
2017
- 2017-08-25 CN CN201780065093.8A patent/CN109890371A/zh active Pending
- 2017-08-25 CA CA3034895A patent/CA3034895A1/en active Pending
- 2017-08-25 RU RU2019105953A patent/RU2764716C2/ru active
- 2017-08-25 JP JP2019510456A patent/JP7096813B2/ja active Active
- 2017-08-25 US US16/328,678 patent/US11103499B2/en active Active
- 2017-08-25 BR BR112019003811-6A patent/BR112019003811A2/pt active Search and Examination
- 2017-08-25 AU AU2017315947A patent/AU2017315947B2/en active Active
- 2017-08-25 WO PCT/US2017/048748 patent/WO2018039642A1/en unknown
- 2017-08-25 EP EP17844542.5A patent/EP3503879A4/en active Pending
- 2017-08-25 KR KR1020197008299A patent/KR102374044B1/ko active IP Right Grant
- 2017-08-28 TW TW106129169A patent/TW201815387A/zh unknown
-
2021
- 2021-03-29 US US17/215,354 patent/US20210228508A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019524850A (ja) | 2019-09-05 |
US11103499B2 (en) | 2021-08-31 |
AU2017315947A1 (en) | 2019-03-07 |
TW201815387A (zh) | 2018-05-01 |
CA3034895A1 (en) | 2018-03-01 |
WO2018039642A1 (en) | 2018-03-01 |
JP7096813B2 (ja) | 2022-07-06 |
RU2019105953A3 (pt) | 2020-11-27 |
EP3503879A4 (en) | 2020-04-29 |
RU2764716C2 (ru) | 2022-01-19 |
CN109890371A (zh) | 2019-06-14 |
US20210228508A1 (en) | 2021-07-29 |
KR102374044B1 (ko) | 2022-03-14 |
RU2019105953A (ru) | 2020-09-28 |
AU2017315947B2 (en) | 2022-12-01 |
EP3503879A1 (en) | 2019-07-03 |
US20190183885A1 (en) | 2019-06-20 |
KR20190042056A (ko) | 2019-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019003811A2 (pt) | composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição | |
CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
BR112019003932A2 (pt) | composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto | |
BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
BR112017000528A2 (pt) | moduladores dos receptores toll-like para o tratamento do hiv | |
MX2019011904A (es) | Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos. | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
BR112012032282A2 (pt) | administração transdérmica de memantina | |
BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
BR112018007947A2 (pt) | uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash | |
BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
BR112017023147A2 (pt) | azabenzimidazóis e seu uso como moduladores do receptor de ampa | |
BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
CL2009002017A1 (es) | Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria. | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
UY36123A (es) | Derivados de carboxamida | |
BR112016005317A2 (pt) | derivados de quinazolina e seu uso como inibidores de dna metiltransferase | |
BR112018004719A2 (pt) | composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto | |
MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15V | Prolongation of time limit allowed |
Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |